Market Tracker

04/24 5:14am ET

Innoviva Inc (NASDAQ:INVA)

12.52
Delayed Data
As of Apr 21
 -0.07 / -0.56%
Today’s Change
8.67
Today|||52-Week Range
14.55
+17.01%
Year-to-Date
Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents
Apr 20 / TheStreet.com - Paid Partner Content
Innoviva Says It Fends Off Sarissa Dissidents
Apr 20 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close12.59
Today’s open12.61
Day’s range12.36 - 12.73
Volume1,377,269
Average volume (3 months)1,202,829
Market cap$1.4B
Dividend yield7.99%
Data as of 04/21/2017

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+132.83%
Earnings growth (next 5 years)+3.00%
Revenue growth (last year)+117.48%
P/E ratio23.6
Price/Sales8.95
Price/Book--

Competitors

 Today’s
change
Today’s
% change
PBYIPuma Biotechnology I...-0.50-1.33%
EGRXEagle Pharmaceutical...-1.25-1.39%
AERIAerie Pharmaceutical...-1.00-2.37%
ARRYArray Biopharma Inc-0.15-1.79%
Data as of 04/21/2017

Financials

Next reporting dateApril 27, 2017
EPS forecast (this quarter)$0.25
Annual revenue (last year)$147.4M
Annual profit (last year)$59.5M
Net profit margin40.39%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Michael W. Aguiar
Chief Financial Officer &
Senior Vice President
Eric d'Esparbes
Corporate headquarters
South San Francisco, California

Forecasts